|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:692011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ionov Y, Peinado MA, Malkhosyan S, Shibata
D and Perucho M: Ubiquitous somatic mutations in simple repeated
sequences reveal a new mechanism for colonic carcinogenesis.
Nature. 363:558–561. 1993. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nonaka R, Miyake Y, Hata T, Kagawa Y, Kato
T, Osawa H, Nishimura J, Ikenaga M, Murata K, Uemura M, et al:
Circulating miR-103 and miR-720 as novel serum biomarkers for
patients with colorectal cancer. Int J Oncol. 47:1097–1102. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Jiang H, Fu XG and Chen YT: Serum level of
endothelial cell-specific molecule-1 and prognosis of colorectal
cancer. Genet Mol Res. 14:5519–5526. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jia J, Zheng X, Chen Y, Wang L, Lin L, Ye
X, Chen Y, Chen D and Dettke M: Stage-dependent changes of
preoperative neutrophil to lymphocyte ratio and platelet to
lymphocyte ratio in colorectal cancer. Tumour Biol. 36:9319–9325.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Šunderić M, Šedivá A, Robajac D, Miljuš G,
Gemeiner P, Nedić O and Katrlík J: Lectin-based protein microarray
analysis of differences in serum alpha-2-macroglobulin
glycosylation between patients with colorectal cancer and persoons
without cancer. Biotechnol Appl Biochem. 63:457–464. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li Y, Fu XH, Yuan JQ, Yang ZY, Mao C, Dong
XM, Tang JL and Wang SY: Colorectal cancer: Using blood samples and
tumor tissue to detect K-ras mutations. Expert Rev Anticancer Ther.
15:715–725. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takahashi N, Yamada Y, Furuta K, Nagashima
K, Kubo A, Sasaki Y, Shoji H, Honma Y, Iwasa S, Okita N, et al:
Association between serum ligands and the skin toxicity of
anti-epidermal growth factor receptor antibody in metastatic
colorectal cancer. Cancer Sci. 106:604–610. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zampino MG, Magni E, Santoro L, Zorzino L,
Dell'Orto P, Sonzogni A, Fazio N, Monfardini L, Chiappa A, Biffi R
and de Braud F: Epidermal growth factor receptor serum (sEGFR)
level may predict response in patients with EGFR-positive advanced
colorectal cancer treated with gefitinib? Cancer Chemother
Pharmacol. 63:139–148. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Spano JP, Lagorce C, Atlan D, Milano G,
Domont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere JF,
et al: Impact of EGFR expression on colorectal cancer patient
prognosis and survival. Ann Oncol. 16:102–108. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Cheirsilpa A, Ruangvejvorachai P, Karalak
A, Sangprakarn S, Pummai S and Sangrajrang S: Determination of
epidermal growth factor receptor (EGFR) in patients with colorectal
cancer. Cancer Ther. 5:137–142. 2007.
|
|
12
|
Arteaga CL: The Epidermal Growth Factor
Receptor: From Mutant Oncogene in Non-human Cancers to Therapeutic
Target in Human Neoplasia. J Clin Oncol. 19 (18 Suppl):32S–40S.
2001.PubMed/NCBI
|
|
13
|
Yarden Y: The EGFR family and its ligands
in human cancer. signalling mechanisms and therapeutic
opportunities. Eur J Cancer. 37 Suppl 4:S3–S8. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goldstein NS and Armin M: Epidermal growth
factor receptor immunohistochemical reactivity in patients with
American Joint Committee on Cancer Stage IV colon adenocarcinoma:
Implications for a standardized scoring system. Cancer.
92:1331–1345. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mourtzikou A, Stamouli M, Kroupis C,
Christodoulou S, Skondra M, Kastania A, Pectasides D, Athanasas G
and Dimas C: Evaluation of carcinoembryonic antigen (CEA),
epidermal growth factor receptor (EGFR), epithelial cell adhesion
molecule EpCAM (GA733-2), and carbohydrate antigen 19-9 (CA 19-9)
levels in colorectal cancer patients and correlation with
clinicopathological characteristics. Clin Lab. 58:441–448.
2012.PubMed/NCBI
|
|
16
|
Guo GF, Cai YC, Zhang B, Xu RH, Qiu HJ,
Xia LP, Jiang WQ, Hu PL, Chen XX, Zhou FF and Wang F:
Overexpression of SGLT1 and EGFR in colorectal cancers showing a
correlation with the prognosis. Med Oncol. 28 Suppl 1:S197–S203.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
McKay JA, Murray LJ, Curran S, Ross VG,
Clark C, Murray GI, Cassidy J and McLeod HL: Evaluation of the
epidermal growth factor receptor (EGFR) in colorectal tumors and
lymph node metastases. Eur J Cancer. 38:2258–2264. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mohhamadi G, Jamialahmadi K, Lary S and
Ghaffarzadegan K: Expression of
membranousepidermalgrowthfactorreceptor in colorectal
adenocarcinoma and its correlation with clinico pathological
features. Pak J Biol Sci. 14:357–362. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Abd El, All HS, Mishriky AM and Mohamed
FA: Epidermal growth factor receptor in colorectal carcinoma:
Correlation with clinico-pathological prognostic factors.
Colorectal Dis. 10:170–178. 2008.PubMed/NCBI
|
|
20
|
AJCC (American Joint Committee on Cancer)
Cancer Staging Manual. 7th. Edge SB, Byrd DR, Compton CC, et al:
Springer; New York: pp. 1432010
|
|
21
|
Karnofsky DA and Burchenal JH: The
Clinical Evaluation of Chemotherapeutic Agents in CancerMacLeod CM:
Evaluation of Chemotherapeutic Agents. Columbia Univ Press; New
York: pp. 1961949
|
|
22
|
Schwartz LH, Litière S, de Vries E, Ford
R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J,
et al: RECIST 1.1-Update and clarification: From the RECIST
committee. Eur J Cancer. 62:132–137. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Siegel RL, Fedewa SA, Miller KD,
Goding-Sauer A, Pinheiro PS, Martinez-Tyson D and Jemal A: Cancer
statistics for Hispanics/Latinos, 2015. Cancer J Clin. 65:457–480..
2015. View Article : Google Scholar
|
|
24
|
Sturgeon CM, Duffy MJ, Stenman UH, Lilja
H, Brünner N, Chan DW, Babaian R, Bast RC Jr, Dowell B, Esteva FJ,
et al: National Academy of Clinical Biochemistry laboratory
medicine practice guidelines for use of tumor markers in
testicular, prostate, colorectal, breast, and ovarian cancers. Clin
Chem. 54:e11–e79. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Duffy MJ, vanDalen A, Haglund C, Hansson
L, Holinski-Feder E, Klapdor R, Lamerz R, Peltomaki P, Sturgeon C
and Topolcan O: Tumour markers in colorectal cancer: European Group
on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer.
43:1348–1360. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Romero-Ventosa EY, Blanco-Prieto S,
González-Piñeiro AL, Rodríguez-Berrocal FJ, Piñeiro-Corrales G and
de la Cadena Páez M: Pretreatment levels of the serum biomarkers
CEA, CYFRA 21-1, SCC and the soluble EGFR and its ligands, EGF,
TGF-alpha, HB-EGF in the prediction of outcome in erlotinib treated
non-small-cell lung cancer patients. Springerplus. 4:1712015.
View Article : Google Scholar : PubMed/NCBI
|
